LifeVantage Small Cap Equity Review

"Lifevantage Corporation is in the midst of a turnaround story, and investors who take a closer look at the company may find an idea most everyone else is overlooking while searching for something a little sexier," says Brumley. The declining sales trend seen between 2006 and 2008 has been reversed, in spades. Fiscal 2010's $11.5 million in revenue is a record, even if it was paired with a record loss of $11 million. The numbers and the way Lifevantage's fiscal calendar falls, however, may obscure something very compelling that's just unfolded in the last three quarters... the company has swung to a profit, and just posted its best quarterly sales ever. It managed to turn $10.0 million in revenue last quarter into a profit of $792,000. Brumley adds "Just to put it into perspective, this supplement distributor generated $7.46 million in revenue for the prior quarter (a record at the time), and generated $6.4 million in sales for the quarter before that (also a record at the time). The bottom line has been reliable too, with an operating per-share profit of $0.01 three quarters ago, what would have been about $0.01 worth of per-share profit two quarters ago (a big accounting benefit boosted the total), and it posted earnings of about $0.01 per share for the most recently-completed quarter." Unlike so many other pill and supplement makers/distributors, Lifevantage has something unique, effective, and patented - Protandim. This supplement improves a user's innate antioxidant protection, and the claim has been verified - repeatedly - in clinical studies. As such, the organization clearly has something that some corporations never find, which is a marketable product and a business model that works.